Another European patent has been granted regarding the RayPilot® system for increased precision in the radiotherapy of prostate cancer. The purpose of the RayPilot®, "which is similar in it's functionality to a GPS system", is to allow less irradiation of healthy tissue, thereby reducing undesirable side effects, and to increase the targeted radiation dose to the tumor, thereby increasing local control.
The granted patent relates to the consumable in the RayPilot® system that is a micro-transmitter implanted in the tumor area, continuously providing the exact location of the tumor in real time throughout the radiotherapy treatment. In addition to that, the transmitter device confirms the patient's identity and the true in-situ radiation dose delivered. The granted patent concerns the design of the transmitter/dosimeter device, allowing it to fulfill it's functions in an easy manner with a minimum of components.
All these features aim to boost security and safety in today's cancer therapy, where it is not uncommon for the wrong patient to receive a given treatment fraction, or to have the wrong dose delivered to the tumor. What is more, certain internal organs may move during a treatment fraction, so that the radiation misses the tumor and instead hits on healthy surrounding tissue.
A problem with current treatment protocols is that they are based on the tumor being positioned prior to treatment using x-rays (portal imaging or CBCT) while there is no continuous monitoring of tumor location during the time that the radiation is delivered.
In 2012 the Sahlgrenska University Hospital in Gothenburg published a scientific poster detailing experience using the RayPilot® which clearly shows that during the radiation treatment of prostate cancer, the tumor can move more than 1 cm. Because of this fact, the precautionary measure to account for potential organ motion today is a significant margin around the tumor which comes with the risk of significant side effects such as incontinence, impotence and continuous bleeding from the rectum.
In order to reduce the margin around the target tumor, and thereby reduce the risk of side effects clinicians need a more precise and continuous monitoring of the real tumor location, which is exactly what RayPilot® does.
It is critical to know that the radiation is delivered to the right place, and it is also important to be sure that the correct dose of radiation is given to the tumor area.
An example of this is a notable case in France where a number of Radiotherapy clinicians were sentenced to prison for manslaughter in February 2013 after 450 prostate cancer patients received the wrong radiation doses. Of these, 12 men received fatal doses of radiation.
In the upcoming version of RayPilot® that has now received European patent protection, the true in-situ radiation dose to the tumor area will be displayed and recorded, which can allow the clinicians to avoid accidents due to incorrect delivered radiation dose, thereby preventing radiation poisoning and even death.
The RayPilot® is currently installed both for clinical use and for future research in clinics in Sweden, Denmark, Germany and Italy. Today, the system is approved for positioning and patient identification during prostate cancer, but the technology is supposed to also be used in other radiotherapy applications including breast, GYN, liver and childhood. These are some cancer localizations wherein intra-fraction tumor motion poses a high risk.
For further information please contact:
Tomas Gustafsson, CEO of Micropos Medical AB (publ), +46-31-772 80 99
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) develops and sells products for the future of precision radiotherapy.
The company’s first product is the RayPilot® system for increased precision in radiotherapy of prostate cancer. The RayPilot® system is an electromagnetic positioning system that enables real time position of the prostate for a fast and objective set-up and for continuous tracking during the treatment. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; a transmitter that is placed in the ROI, a receiving system that is placed directly on any existing treatment coach and software that continuously shows where the tumor is and where to beam. The transmitter is removed after the final treatment in order to enable MRI follow-up. The RayPilot® system is CE-Marked and thus approved for European use.
Micropos Medical AB (publ) is listed on AktieTorget under stock symbol MPOS.